Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lepodisiran - Eli Lilly and Company

Next Previous
Drug Profile

Lepodisiran - Eli Lilly and Company

Alternative Names: DCR-CM2; LP(a)-siRNA - Eli Lilly and Company; LY 3819469

Latest Information Update: 03 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dicerna Pharmaceuticals
  • Developer Dicerna Pharmaceuticals; Eli Lilly and Company
  • Class Amides; Amino sugars; Antihyperlipidaemics; Cardiovascular therapies; Drug conjugates; Pyrrolidines; Small interfering RNA
  • Mechanism of Action Lipoprotein A expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hyperlipoproteinaemia
  • Phase I Liver disorders

Most Recent Events

  • 17 Jul 2026 Eli Lilly and Company completes phase-I clinical trials in Liver disorders in USA, Hungary (SC) (NCT06916078)
  • 02 Jun 2026 Eli Lilly and Company initiates a phase-III ACCLAIM-CTA trial for Hyperlipoproteinaemia (In adults, In the elderly) in USA (SC) (NCT07613294)
  • 31 May 2026 Eli Lilly and Company plans a phase-III ACCLAIM-CTA trial for Hyperlipoproteinaemia (In adults, In the elderly) in USA, Australia, Czech Republic, Hungary, Netherlands, Spain, United Kingdom (SC) (NCT07613294)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top